Ceftazidime: Difference between revisions

No edit summary
(Remove disease-specific dosing covered by dynamic SMW tables)
 
(3 intermediate revisions by 2 users not shown)
Line 1: Line 1:
==General==
==General==
*Type: Third generation [[Is DrugClass::cephalosporin]]
*Type: [[Is Generation::3rd generation]] [[Is DrugClass::cephalosporin]]
*Dosage Forms: injectable solution, powder for injection
*Dosage Forms: injectable solution, powder for injection
*Dosage Strengths: injectable solution: 20mg/mL, 40mg/mL; powder for injection: 500mg, 1g, 2g, 6g
*Dosage Strengths: injectable solution: 20mg/mL, 40mg/mL; powder for injection: 500mg, 1g, 2g, 6g
Line 10: Line 10:
*1 g IV/IM q8-12h
*1 g IV/IM q8-12h
**Max: 6 g/day
**Max: 6 g/day
===[[Pneumonia]], Hospital-acquired or ventilator-associated===
===Indications by Disease===
*2 g IV q8h x7 days
{{#ask: [[Has DrugName::Ceftazidime]] [[Has Population::Adult]]
|?Treats disease=Disease
|?Has Dose=Dose
|?Has Context=Context
|format=table
|limit=50
|mainlabel=-
|headers=show
|sort=Treats disease
}}


==Pediatric Dosing==
==Pediatric Dosing==
Line 25: Line 34:
***Max: 6 g/day
***Max: 6 g/day
***Reserve high dose for immunocompromised, cystic fibrosis, or meningitis
***Reserve high dose for immunocompromised, cystic fibrosis, or meningitis
===Indications by Disease===
{{#ask: [[Has DrugName::Ceftazidime]] [[Has Population::Pediatric]]
|?Treats disease=Disease
|?Has Dose=Dose
|?Has Context=Context
|format=table
|limit=50
|mainlabel=-
|headers=show
|sort=Treats disease
}}


==Special Populations==
==Special Populations==

Latest revision as of 02:57, 20 March 2026

General

  • Type: 3rd generation cephalosporin
  • Dosage Forms: injectable solution, powder for injection
  • Dosage Strengths: injectable solution: 20mg/mL, 40mg/mL; powder for injection: 500mg, 1g, 2g, 6g
  • Routes of Administration: IV, IM
  • Common Trade Names: Fortaz, Tazicef, Tazidime

Adult Dosing

Infections, Bacterial

  • 1 g IV/IM q8-12h
    • Max: 6 g/day

Indications by Disease

DiseaseDoseContext
Brain abscess2gm IV q8hrTrauma/Post-surgical
Discitis2g IV three times dailyInpatient Therapy
Neutropenic fever2g IV q8hrsInpatient monotherapy
Peritoneal dialysis-associated peritonitis1g IP dailyEmpiric IP
Pneumonia (main)2g q8hHAP, High Risk

Pediatric Dosing

Infections, Bacterial

  • Neonates 0-7 days old
    • 100 mg/kg/day IM/IV divided q12h
  • Neonates >7 days old, <1200g
    • 100mg/kg/day IM/IV divided q12h
  • Neonates >7 days old, >1200g
    • 150mg/kg/day IM/IV divided q8h
  • 1mo - 12yo
    • 90-150 mg/kg/day IM/IV divided q8h
      • Max: 6 g/day
      • Reserve high dose for immunocompromised, cystic fibrosis, or meningitis


Indications by Disease

DiseaseDoseContext
Brain abscess50mg/kg IV q8hrs (max 2g/dose)Pediatric Trauma/Post-surgical
Osteomyelitis30mg/kg IV q12 hNewborn
Osteomyelitis50mg/kg q8hrChildren

Special Populations

  • Pregnancy: C; May use during pregnancy
  • Lactation: No known risk
  • Renal Dosing
    • Adult
      • CrCl 31-50: Give q12h
      • CrCl 16-30: Give q24h
      • CrCl 6-15: 1 g x1, then 500mg q24h
      • CrCl <5: 1 g x1, then 500mg q48h
      • HD: 1 g x1, then give 1 g after dialysis, no supplement
      • PD: 1 g x1, then 500mg q24h, no supplement
    • Pediatric
      • CrCl 30-50: Give q12h
      • CrCl 10-29: Give q24h
      • CrCl <10: Give q48h
      • HD/PD: No supplement
  • Hepatic Dosing
    • Adult: No adjustment
    • Pediatric: No adjustment

Contraindications

  • Allergy to class/drug
  • Caution:
    • Hypersensitivity to [penicillin]
    • Renal impairment
    • Concurrent nephrotoxic agent
    • Seizure disorder
    • Recent abx-associated colitis

Adverse Reactions

Serious

Common

Pharmacology

  • Half-life: 1.9h
  • Metabolism: Minimal
  • Excretion: Urine primarily
  • Mechanism of Action: Bactericidal; inhibits cell wall mucopeptide synthesis

Antibiotic Sensitivities[1]

Group Organism Sensitivity
Gram Positive Strep. Group A, B, C, G S
Strep. Pneumoniae S
Viridans strep I
Strep. anginosus gp X1
Enterococcus faecalis R
Enterococcus faecium X1
MSSA I
MRSA R
CA-MRSA R
Staph. Epidermidis I
C. jeikeium R
L. monocytogenes R
Gram Negatives N. gonorrhoeae I
N. meningitidis I
Moraxella catarrhalis S
H. influenzae S
E. coli S
Klebsiella sp S
E. coli/Klebsiella ESBL+ R
E coli/Klebsiella KPC+ R
Enterobacter sp, AmpC neg S
Enterobacter sp, AmpC pos R
Serratia sp S
Serratia marcescens X1
Salmonella sp S
Shigella sp S
Proteus mirabilis S
Proteus vulgaris S
Providencia sp. S
Morganella sp. S
Citrobacter freundii R
Citrobacter diversus S
Citrobacter sp. S
Aeromonas sp S
Acinetobacter sp. I
Pseudomonas aeruginosa S
Burkholderia cepacia S
Stenotrophomonas maltophilia I
Yersinia enterocolitica I
Francisella tularensis X1
Brucella sp. X1
Legionella sp. R
Pasteurella multocida X1
Haemophilus ducreyi S
Vibrio vulnificus X1
Misc Chlamydophila sp X1
Mycoplasm pneumoniae X1
Rickettsia sp X1
Mycobacterium avium X1
Anaerobes Actinomyces X1
Bacteroides fragilis R
Prevotella melaninogenica S
Clostridium difficile X1
Clostridium (not difficile) S
Fusobacterium necrophorum X1
Peptostreptococcus sp. S

Key

  • S susceptible/sensitive (usually)
  • I intermediate (variably susceptible/resistant)
  • R resistant (or not effective clinically)
  • S+ synergistic with cell wall antibiotics
  • U sensitive for UTI only (non systemic infection)
  • X1 no data
  • X2 active in vitro, but not used clinically
  • X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
  • X4 active in vitro, but not clinically effective for strep pneumonia

See Also

References

  1. ↑ Sanford Guide to Antimicrobial Therapy 2014
Retrieved from "https://www.wikem.org/w/index.php?title=Ceftazidime&oldid=386637"